ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
30 announcements
Aptus Pharma got BSE in-principle approval for a preferential issue of 15,99,270 shares at a minimum Rs. 280 each. The issue is worth about Rs. 44.78 Crore.
H1 FY27 revenue ₹48.92 Cr, EBITDA ₹7.68 Cr (15.7% margin), PAT ₹5.07 Cr; revenue exceeds full FY26 (₹46.57 Cr). Trading-heavy model with rising receivables and negative operating cash flow.
Aptus Pharma Ltd reported revenue from operations of ₹48.9 Cr (+239.6% YoY) and net profit of ₹5.1 Cr (+200.0% YoY) for H1 FY27.
Aptus Pharma Limited submitted the Regulation 74(5) compliance certificate for the quarter and half-year ended 30th September 2026, as received from its registrar.
Aptus Pharma Ltd issued a corrigendum to its 16th AGM notice regarding inadvertent errors in the explanatory statement for item no. 3.
Aptus Pharma Limited's Board has approved raising ₹44.88 Crore through a preferential equity issue. Funds will support manufacturing capacity expansion, working capital, and Pan-India growth initiatives.
Aptus Pharma has filed its Annual Report for FY 2025-26 with the exchange. The report includes the notice for the upcoming 16th Annual General Meeting.
Aptus Pharma Limited issued a notice for its 16th AGM on September 14, 2026, which includes a proposal for a preferential allotment of equity shares.
Aptus Pharma approved a preferential issue of 16,02,870 equity shares at Rs. 280 per share, raising approximately Rs. 44.88 Crore. The board also scheduled the 16th AGM.
Aptus Pharma Limited issued a clarification regarding typographical errors in its August 8, 2026, board meeting outcome. The correction specifies the meeting venue and annexure titles.
Aptus Pharma approved a preferential issue of 16,10,100 equity shares to various allottees. The company also fixed the Annual General Meeting date for September 14, 2026.
Aptus Pharma Ltd will hold a board meeting on August 8, 2026, to consider a proposal for raising funds through preferential allotment of equity securities.
Aptus Pharma Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026, in compliance with SEBI regulatory requirements.
Aptus Pharma Limited has been assigned a 'CARE BB; Stable' issuer rating by CARE Ratings. The rating reflects the company's modest scale of operations.
Aptus Pharma's board approved a ₹51 Crore fund raise via preferential allotment and debt. The move supports business expansion, pending shareholder and regulatory approvals.
Aptus Pharma scheduled a board meeting for June 12, 2026, to consider fund-raising via preferential allotment and bank borrowings. The trading window remains closed.
Aptus Pharma (BSE SME) reports strong growth in FY26 following its 2025 listing. The company operates an asset-light, marketing-focused model with 250+ formulations across diverse therapeutic segments.
Aptus Pharma Limited took over the Baby Care Room at Rajkot Hirasar Airport for brand promotion. This initiative aims to enhance visibility for its upcoming product portfolio.
Milly Chetan Lalseta acquired 18,000 shares of Aptus Pharma Limited via an internal promoter group transfer. The off-market transaction consolidates promoter holding at 8.64%.
Promoter Gaurang Rameshchandra Thakker acquired 18,000 shares of Aptus Pharma Ltd via an off-market transfer. His stake increased to 8.64%, consolidating promoter-group control.
Promoter Chatrabhuj Vallabhbhai Butani sold 1,24,000 shares through an off-market inter-se transfer. His individual stake decreased from 3.28% to 1.47%.
Promoter Ghanshyam Vinubhai Pansuriya acquired 14,000 shares via an off-market inter-se transfer. This internal restructuring increases his stake to 5.31% without changing aggregate promoter control.
Promoter Kapilbhai Chandarana acquired 10,000 Aptus Pharma Ltd shares through an off-market transaction. His total holding increased to 11.44%, signaling continued promoter confidence.
Aptus Pharma Limited submitted its Monitoring Agency Report for the period ended March 31, 2026, confirming full utilization of ₹13.02 Crore raised through its IPO. The report, issued by CARE Ratings Limited, shows NIL deviation from the objects stated in the offer document, covering working capital, capital expenditure, and corporate purposes.
Aptus Pharma Limited submitted its statement of utilization of IPO proceeds for the period ended March 31, 2026. The company confirmed it raised and fully utilized ₹13.02 Crore across objects including working capital and capital expenditure, reporting zero deviation or variation.
Aptus Pharma Limited reported robust FY26 financial results, with total revenue doubling to ₹46.71 Crore and PAT increasing by 49% to ₹4.62 Crore. The company expanded its portfolio to over 250 formulations and services 25K+ retail outlets. Aptus aims for a pan-India presence by 2030 through its asset-light manufacturing model and strategic vertical expansion.
Aptus Pharma Ltd reported revenue from operations of ₹32.2 Cr (+117.6% YoY) and net profit of ₹2.9 Cr (+61.1% YoY) for H2 FY26.
Aptus Pharma Limited reported a revenue of ₹46.57 Crore and a net profit of ₹4.62 Crore for the financial year ended March 31, 2026. The Board also fixed May 12, 2026, as the record date for a 3:2 bonus share issue, following shareholder approval via postal ballot.
Aptus Pharma Ltd informed BSE that Regulation 24A of SEBI (LODR) Regulations, 2015, regarding the Annual Secretarial Compliance Report, is not applicable to the company. As an entity listed on the SME Exchange, it falls under the exemptions provided in Regulation 15(2)(b).
Aptus Pharma Ltd has scheduled a Board Meeting on April 27, 2026, to consider and approve audited financial results for the half-year and year ended March 31, 2026. The company also announced the closure of its trading window until 48 hours after the results declaration.